

# Genomic Insights into Pediatric Intestinal Inflammatory and Eosinophilic Disorders using Single-cell RNA-sequencing

1 Marissa R. Keever-Keigher<sup>1</sup>, Lisa Harvey<sup>1</sup>, Veronica Williams<sup>1</sup>, Carrie A. Vyhldal<sup>3</sup>, Atif A.  
2 Ahmed<sup>4</sup>, Jeffery J. Johnston<sup>1</sup>, Daniel A. Louiselle<sup>1</sup>, Elin Grundberg<sup>1,2</sup>, Tomi Pastinen<sup>1,2</sup>, Craig A.  
3 Friesen<sup>1,2</sup>, Rachel Chevalier<sup>1,2</sup>, Craig Smail<sup>1, 2, †, \*</sup>, Valentina Shakhnovich<sup>1,2,5, †, #</sup>

4 <sup>1</sup> Children's Mercy Kansas City, Kansas City, MO, USA

5 <sup>2</sup> University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA

6 <sup>3</sup> KCAS Bioanalytical & Biomarker Services, Shawnee, KS, USA

7 <sup>4</sup> Seattle Children's Hospitals-University of Washington, Seattle, WA, USA

8 <sup>5</sup> Ironwood Pharmaceuticals, Boston, MA, USA

9 <sup>†</sup> Joint senior authors

10 <sup>#</sup> Current affiliation with Ironwood Pharmaceuticals has no scientific or financial bearing on the work  
11 presented herein.

12 **\* Correspondence:**

13 Craig Smail

14 csmail@cmh.edu

15

## 16 Abstract

17 Chronic inflammation of the gastrointestinal tissues underlies gastrointestinal inflammatory  
18 disorders, leading to tissue damage and a constellation of painful and debilitating symptoms. These  
19 disorders include inflammatory bowel diseases (Crohn's disease and ulcerative colitis), and  
20 eosinophilic disorders (eosinophilic esophagitis and eosinophilic duodenitis). Gastrointestinal  
21 inflammatory disorders can often present with overlapping symptoms necessitating the use of  
22 invasive procedures to give an accurate diagnosis. This study used peripheral blood mononuclear  
23 cells from individuals with Crohn's disease, ulcerative colitis, eosinophilic esophagitis, and  
24 eosinophilic duodenitis to better understand the alterations to the transcriptome of individuals with  
25 these diseases and identify potential markers of active inflammation within the peripheral blood of  
26 patients that may be useful in diagnosis. Single-cell RNA-sequencing was performed on peripheral  
27 blood mononuclear cells isolated from the blood samples of pediatric patients diagnosed with  
28 gastrointestinal disorders, including Crohn's disease, ulcerative colitis, eosinophilic esophagitis,  
29 eosinophilic duodenitis, and controls with histologically healthy gastrointestinal tracts. We identified  
30 730 (FDR < 0.05) differentially expressed genes between individuals with gastrointestinal disorders  
31 and controls across eight immune cell types. There were common patterns among GI disorders, such  
32 as the widespread upregulation of *MTRNR2L8* across cell types, and many differentially expressed  
33 genes showed distinct patterns of dysregulation among the different gastrointestinal diseases  
34 compared to controls, including upregulation of *XIST* across cell types among individuals with  
35 ulcerative colitis and upregulation of Th2-associated genes in eosinophilic disorders. These findings  
36 indicate both overlapping and distinct alterations to the transcriptome of individuals with  
37 gastrointestinal disorders compared to controls, which provide insight as to which genes may be  
38 useful as markers for disease in the peripheral blood of patients.

## 39 Introduction

40 In genetically predisposed individuals, chronic overactivation of the inflammatory response damages  
41 tissues along the gastrointestinal (GI) tract frequently resulting in painful and debilitating symptoms  
42 (1, 2). GI inflammatory disorders include inflammatory bowel disease (IBD) and eosinophilic  
43 gastrointestinal diseases such as eosinophilic esophagitis (EoE) and eosinophilic duodenitis (EoD).  
44 IBD is characterized by chronic relapsing neutrophilic inflammation of the intestine and can be  
45 divided into two main subtypes based on the site and characteristics of inflammation, with Crohn's  
46 disease (CD) occurring within any portion of the gut and ulcerative colitis (UC) being confined to the  
47 colon. IBD affects patients of all ages, with approximately a quarter of patients are diagnosed before  
48 adulthood and incidence of pediatric IBD is increasing (3, 4). EoE and EoD are Th-2 mediated  
49 inflammatory disorders which can cause dysphagia, vomiting, abdominal pain, and stricturing.  
50 Histologically EoE and EoD are characterized by mucosal eosinophilia (5) and may exist  
51 independently or as a comorbid condition with either form of IBD. However eosinophilic  
52 infiltration of the mucosa may also precede histologic evidence of IBD (crypt distortion, cryptitis  
53 with crypt abscesses, mucus depletion from goblet cells, granulomas), sometimes by years (6, 7),  
54 further complicating the ability to differentiate concomitant eosinophilic disease from early  
55 harbingers of IBD .

56 Differentiating between UC and CD or between early IBD and EoE/EoD can help direct therapy. As  
57 example, CD patients benefit from early biologic therapy (8), and colectomy is only curative in UC  
58 (9). Patients with two concomitant diseases (i.e. EoE and CD) may affect the same area but exhibit  
59 different histology and symptoms and require different treatments (10). Additionally, early  
60 knowledge of whether mucosal eosinophilia is burgeoning IBD can allow early and appropriate

61 intervention. The pediatric population with IBD and EoE/EoD are particularly vulnerable to growth  
62 failure (11, 12) and interruptions in social-emotional development (13) and will require decades of  
63 healthcare for their condition. Since disease diagnosis and follow up evaluation currently require  
64 invasive endoscopic testing, non-invasive diagnostics and targeted therapies are particularly valuable  
65 to this subset of patients.

66 Characterizing the role of specific immune cell populations in GI diseases has aided in recognizing  
67 aberrant processes that underlie these conditions, initiating an important shift in the treatment  
68 paradigm away from systemic, non-targeted immunosuppression (fraught with many unwanted side  
69 effects) to targeted modulation at the site of disease activity (14). Continued identification of novel  
70 therapeutic targets and molecular signatures of disease is pivotal for advancing and optimizing  
71 treatment options for chronic immune-mediated inflammatory disorders. In the IBD-affected GI tract,  
72 dendritic cells (DCs)—antigen presenting cells belonging to the innate immune system—exhibit up-  
73 regulation of microbial recognition receptors and increased cytokine production (15) that appears to  
74 induce inflammation through activation of T cells (16). T cells play a crucial role in immune  
75 homeostasis (17, 18), and dysregulation of cytokine signaling in CD4<sup>+</sup> T cells of the GI tract has been  
76 shown to lead to pathogenic inflammation (18, 19). T cells also play a key role in eosinophilic  
77 disorders of the GI tract, as overexpression of interleukin 5 (IL-5) in CD2<sup>+</sup> T cells is sufficient to  
78 produce eosinophilia in the esophagus and small intestine of transgenic mice (20).

79 In addition to contributing to inflammation and tissue damage at lesion sites in the GI tract, evidence  
80 of altered gene expression and signaling among immune cells in peripheral blood may be reflective  
81 of luminal inflammation (21-23). Information gathered from peripheral blood has the potential to  
82 identify minimally-invasive, diagnosis-specific and/or disease location-specific genetic markers for  
83 GI diseases. Discovery of such biomarkers could potentially decrease the need for repeat endoscopy,  
84 which is invasive, associated with risks, and costly. Furthermore, identification of altered gene  
85 expression within these disorders at the cellular level could yield a more complete understanding of  
86 impacted pathways within specific cell types, and aid in characterizing genetic signatures for future  
87 use in disease sub-typing and drug response applications. However, due to the complex and  
88 multifactorial nature of GI diseases and differences in immune cell response across GI disease sub-  
89 types, reliable indicators of active inflammation have been difficult to characterize within the  
90 peripheral blood of patients to date.

91 In this study, we identified cell-type specific differential gene expression and enrichment of  
92 functional gene ontology terms and pathways in individuals diagnosed with CD, UC, EoE, and EoD  
93 using single-cell RNA-sequencing of peripheral blood mononuclear cells (PBMCs) in a pediatric  
94 patient cohort. Results from this study assist in uncovering the genomic landscape of these  
95 phenotypes, which often present with overlapping symptoms in patients, and aid in identifying robust  
96 markers of disease types within the peripheral blood mononuclear cells of patients.

## 97 **Materials and Methods**

### 98 **Patient Information**

99 Potential study participants were identified via review of the clinical endoscopy schedule and the  
100 electronic medical record (EMR) at the Children's Mercy Hospital (CMH), a tertiary regional  
101 pediatric hospital in the Midwestern United States. To be considered for study inclusion, patients had  
102 to be between 1 month and 21 years of age (inclusive), undergoing both upper and lower endoscopy  
103 with biopsies for clinical purposes, having a reasonable clinical suspicion for a new diagnosis of  
104 immune-mediated inflammatory disease or another clinical indication for undergoing endoscopy

105 (e.g., abdominal pain), and not receiving systemic immunomodulating, immunosuppressive, or  
106 biological drugs. Subjects were recruited on the day of procedure, prior to endoscopy. All subjects  
107 were fasting at least 8 hours for procedural purposes as part of routine medical care. Only those  
108 subjects who provided informed consent (if 18 years of age), or informed assent with parental/legal  
109 guardian consent (if under 18 years of age) were included. All research activities were approved by  
110 the CMH Institutional Review Board. A total of 35 patients seen in the CMH operating room for  
111 routine endoscopy (Kansas City, MO, USA) were included in the study. This cohort consists of 16  
112 males and 19 females ranging in age from 6.17 to 19.25 years with a mean age of 13.3 years. Seven  
113 patients were subsequently diagnosed with CD, nine with EoD, ten with EoE, and three with UC. Six  
114 patients were identified as controls who had no relevant GI pathology on visual or histologic  
115 examination of tissue. Review of individuals' medical charts indicated no bias toward a single drug  
116 therapy in any sub-cohort.

### 117 **PBMC Isolation**

118 Up to 4 mL of whole blood was collected from patients in a sodium heparin tube and stored on ice  
119 until PBMCs were isolated. Automated PBMC isolation was performed using a STEMCELL  
120 Technologies RoboSep-S using the EasySep Direct Human PBMC Isolation Kit (STEMCELL  
121 Technologies Cat No. 19654RF) and following the manufacturer's protocol. After PBMC isolation,  
122 the resulting cell suspension was centrifuged at 300 x g for 8 min, and the supernatant was carefully  
123 aspirated. The cell pellet was resuspended in 1 mL of ACK Lysing Buffer (Thermo Fisher Cat No.  
124 A1049201) and incubated at room temperature for 5 min to remove any remaining RBCs. The cell  
125 suspension was centrifuged at 300 x g for 8 min, and the supernatant was carefully aspirated. Cells  
126 were washed twice with PBS (Thermo Fisher Cat No. 14190144) supplemented with 2% heat-  
127 inactivated FBS (GE Healthcare Cat No. SH30088.03HI), and cell count and viability were assessed  
128 using a Countess II automated cell counter. An aliquot of 300,000 cells was diluted in a total volume  
129 of 200  $\mu$ L of PBS + 2% FBS and frozen at -80°C for downstream DNA isolation and genotyping.  
130 The remaining cells were cryopreserved in aliquots of at least one million cells by centrifuging at 300  
131 x g for 8 min, aspirating the supernatant, and resuspending the cell pellets in Recovery Cell Culture  
132 Freezing Medium (Thermo Fisher Cat No. 12648010). The cell suspensions were transferred to  
133 cryogenic storage vials and were slow-frozen overnight to a temperature of -80°C in a Corning  
134 CoolCell FTS30.

### 135 **DNA Isolation and Genotyping**

136 Aliquots of 300,000 PBMCs frozen in PBS + 2% FBS were thawed at room temperature, and DNA  
137 was isolated using the Qiagen DNeasy Blood & Tissue Kit (Qiagen Cat No. 69506) according to the  
138 manufacturer's protocol. Eluate was concentrated to approximately 50  $\mu$ L using an Eppendorf  
139 Vacufuge Plus, and DNA was quantified using a Qubit dsDNA BR Assay Kit following the  
140 manufacturer's protocol. All DNA samples were selected for high-density genotyping using the  
141 Illumina Global Screening Array (GSAMD-24v1-0) according to protocols recommended by  
142 Illumina.

### 143 **Cell Pooling**

144 Two pools of PBMCs were made. Thawing Medium for PBMC samples consisted of IMDM (ATCC  
145 Cat No. 30-2005) supplemented with 10% heat-inactivated FBS, 100 units/mL of penicillin, and 100  
146  $\mu$ g/mL of streptomycin. For each sample to be thawed, 10 mL of Thawing Medium was prewarmed  
147 in a 37°C bead bath. Cells were thawed in groups of up to five samples at a time. The cryovials were  
148 placed in a 37°C bead bath. When thawed, the cryovials and 15-mL conical tubes containing

149 Thawing Medium were aseptically transferred to the biosafety cabinet. For each sample, 1 mL of  
150 Thawing Medium was added, dropwise, to the cell suspension. The cell suspension was pipette-  
151 mixed and then diluted in the remaining 9 mL of Thawing Medium. The thawed and diluted cells  
152 were left at room temperature while the remaining cells to be pooled were similarly thawed. When all  
153 samples were thawed, the samples were centrifuged at 300 x g for 8 min. The supernatant was  
154 carefully aspirated, and the cell pellets were resuspended in 0.5 mL of room-temperature Thawing  
155 Medium. All samples were placed on ice and then pooled together. The pool was passed through a  
156 40- $\mu$ m nylon mesh cell strainer to remove cell aggregates. The pool was centrifuged at 300 x g for 8  
157 min at 4°C, and the supernatant was carefully aspirated. The cell pellet was resuspended in 1 mL of  
158 cold Thawing Medium, and cell count and viability were assessed using a Countess II automated cell  
159 counter. No fewer than three aliquots per pool were cryopreserved by centrifuging at 300 x g for 8  
160 min at 4°C and resuspending the cell pellets in Recovery Cell Culture Freezing Medium. The cell  
161 suspensions were transferred to cryogenic storage vials and were slow-frozen overnight to a  
162 temperature of -80°C in a Corning CoolCell FTS30.

### 163 **Single-cell Sequencing**

164 Aliquots from each pool were thawed for scRNA-seq. The 10x Genomics Chromium Single Cell 3 $\times$   
165 Reagent Kit v3 was used according to the manufacturer's protocol to target approximately 15,000  
166 cells per scRNA-seq capture. Libraries were sequenced on an Illumina NovaSeq 6000 platform using  
167 2x94 cycle paired-end sequencing.

### 168 **scRNA-seq Alignment and Quality Control**

169 Cell Ranger v 4.0.0 (10x Genomics) was used for read alignment to the GRCh38 (2020) reference  
170 genome, gene counting, and cell calling. Demuxlet (24) was used to demultiplex single-cell data,  
171 assigning reads back to the patient of origin using VCF files associated with each patient.  
172 Additionally, deumuxlet was used to remove data in instances where barcodes were assigned to more  
173 than a single cell.

174 Quality control of cells was performed with the Seurat v 4.9.9 (25) package in R v 4.2.1. Cells with  
175 greater than 20% MT-RNA, fewer than 500 UMIs, and fewer than 0.8  $\log_{10}$  genes per UMI were  
176 removed. Annotation of the cell types of remaining cells was performed with the Azimuth v 0.4.6  
177 package in R using a previously published PBMC reference (26) to annotate cells to eight broad level  
178 one cell types and 30 more specific level two cell types (**Supplementary File 1 Table A**).

### 179 **Pseudobulk Differential Expression Analysis and Functional Analysis**

180 Gene expression data was aggregated by genotype within cell type using AggregateExpression() in  
181 the Seurat R package v 4.9.9. Pseudobulk differential expression analysis of the single-cell data was  
182 performed on the aggregated count data for each defined cell type with edgeR v 3.40.2 (27) in R v  
183 4.2.0. Patient sex and sequencing pool were added to the statistical model to account for biological  
184 variation and batch effects, and a generalized linear model was used to identify differentially  
185 expressed genes (DEGs) between each GI disorder group (CD, UC, EoE, and EoD) and controls  
186 across eight level one cell types and 29 level two cell types. P-values were adjusted for multiple  
187 testing using the Benjamini-Hochberg false discovery rate (FDR), and genes with and FDR < 0.05  
188 were considered significantly differentially expressed.

189 Functional and pathway analysis for DEGs was carried out using the ToppFun (Transcriptome,  
190 ontology, phenotype, proteome, and pharmacome annotations based gene list functional enrichment

191 analysis) tool with default settings from the web-based software ToppGene Suite  
192 (<http://toppgene.cchmc.org>) to identify enriched gene ontology (GO) terms and pathways from  
193 databases including KEGG, Reactome, and BioCarta (28). Terms and pathways with a Benjamini-  
194 Hochberg FDR < 0.05 and a minimum number of three hits in query list were considered to be  
195 significantly enriched.

## 196 **Protein-Protein Interaction Networks**



197 Networks of interactions of DEGs were generated in STRING v 12.0 (29) to visualize gene  
198 relationships and trends within and between cell types and GI disorders. Networks generated with  
199 STRING were imported into Cyotscape v 3.10.0 (30) where node color was used to designate the  
200 direction of fold change observed in GI disorders compared to controls, with red corresponding to  
201 upregulation and blue corresponding to downregulation. Furthermore, functional terms of interest  
202 identified to be enriched in STRING were added to networks.

## 203 **Results**

### 204 **Cell Clustering**

205 A total of 39,622 cells from the 35 individuals in this study passed quality control measures and were  
206 mapped to eight level one cell types and 29 level two cell types (**Figure 1; Supplementary File 1**  
207 **Tables A, B, and C**).

208 **Figure 1. A)** UMAP of 39,622 cells passing quality control measures sorted into eight level one cell  
209 types and into **B)** 29 level two cell types.




210

211 **Effect of Gastrointestinal Disorders on the Transcriptome of Immune Cells**

212 Comparison of gene expression between individuals diagnosed with GI disorders (CD, UC, EoD, and  
 213 EoE) and controls yielded 730 (FDR < 0.05) DEGs (**Figure 2**) across eight level one cell types and  
 214 807 (FDR < 0.05) across 25 level two cell types. A list of significant DEGs found across GI disorders  
 215 within each cell type can be found in **Supplementary File 1 Tables D and E** and volcano plots

216 depicting the results of differential expression analysis for between GI disorders and controls within  
217 all level one cell types can be found in **Supplementary File 2 Figures A-H**.

218 **Figure 2.** Number of differentially expressed genes (DEGs) across level one cell types and GI  
219 disorder subtypes.




220  
221 Relatively few genes showed common patterns of dysregulation across all GI disorders within cell  
222 types: four genes in B cells and DCs, three genes in CD4<sup>+</sup> and CD8<sup>+</sup> T cells, and one gene in both  
223 NK cells and other T cells (**Supplementary File 1 Table D**). Among these genes with shared  
224 patterns of dysregulation were upregulated *MTRNR2L8* in six of the eight level one cell types (B,  
225 CD4<sup>+</sup> T, CD8<sup>+</sup> T, DC, NK, and other T), downregulated *CPA5* in both CD4<sup>+</sup> and CD8<sup>+</sup> T cells, and  
226 downregulated *CST3* in CD4<sup>+</sup> T cells (**Supplementary File 1 Table D**).

227 Additionally, relatively few genes showed similar patterns of differential expression specific to  
228 eosinophilic disorders (EoD and EoE) or IBD (CD and UC) compared to controls. Notable among  
229 genes that shared expression patterns among eosinophilic disorders compared to controls was the  
230 upregulation of *MTRNR2L1* in four level one cell types (B, CD4<sup>+</sup> T, CD8<sup>+</sup> T, and DC), upregulation  
231 of several cell cycle associated genes (*MKI67*, *MELK*, *CLSPN*, *CCNA2*, *TOP2A*, *MCM5*, *CDCA8*,  
232 *MYBL2*, *PCLAF*, *PCNA*, *DLGAP5*, *MCM7*, *UBE2C*, *ZWINT*, *SKA1*, *CCNB1*, *CDK1*, *KIF11*,  
233 *CDKN3*, and *ASPM*) in CD4<sup>+</sup> T cells (**Figure 3; Supplementary File 1 Table D**), and  
234 downregulation of *YBX3* in CD8<sup>+</sup> T cells (**Supplementary File 1 Table D**). In IBD subtypes,  
235 *OR11G2* was upregulated in CD4<sup>+</sup> T and CD8<sup>+</sup> T cells relative to controls (**Supplementary File 1**  
236 **Table D**).



237 **Figure 3.** Informative significantly enriched Gene Ontology terms and pathways among  
 238 differentially expressed genes across level one cell types and GI disorder subtypes identified through  
 239 ToppGene.



240

241 The majority of DEGs did not present with dysregulation in common between GI disorder subtypes;  
 242 thus, many genes had patterns of dysregulation specific to each GI disorder. Notably, in CD, we  
 243 observed upregulation of *CC8T* in CD4<sup>+</sup> T cells, downregulation of *BTN3A2* in CD4<sup>+</sup> TCM cells, and  
 244 upregulation of *ETS2* in DCs. In EoD, we observed upregulation of *FOXMI* and *CCR9* in CD4<sup>+</sup> T  
 245 cells and downregulation of *GADD45B* and *GADD45G* in CD4<sup>+</sup> T cells. In EoE, we observed  
 246 upregulation of *IFNG* in CD4<sup>+</sup> T cells; upregulation of *IER2* in B and CD8<sup>+</sup> naïve T cells;  
 247 upregulation of *EGR1* in three level one cell types (B, CD4<sup>+</sup> T, and CD8<sup>+</sup> T cells) and several level  
 248 two cell types, including naïve CD8<sup>+</sup> T cells and CD4<sup>+</sup> TCM cells, and upregulation of both *EGR3*

249 and *EGR4* in B cells. Within UC, we observed downregulation of several genes in CD8<sup>+</sup> T cells  
250 associated with cytotoxicity, such as *CCL5*, *FGFBP2*, *GZMA*, *GZMB*, *GZMH*, *IFNG*, *NKG7*, and  
251 *PRF1*; upregulation of *NOG*, *REG4*, and *AIF1* in CD8<sup>+</sup> T cells; and upregulation *XIST* in five level  
252 one cell types (B, CD4<sup>+</sup> T, DC, monocytes, and NK) (**Supplementary File 1 Tables D and E**).

253 A subset of DEGs along with citations of literature supporting their role in GI disorders or in the  
254 pathogenesis of inflammation can be found in **Supplementary File 1 Table F**.

### 255 **Enrichment of Functional Gene Ontology Terms among DEGs Associated with** 256 **Gastrointestinal Disorders**

257 Functional analysis of DEGs to identify enriched gene ontology terms and pathways yielded 1037  
258 terms in B cells, 892 terms in CD4<sup>+</sup> T cells, 760 terms in CD8<sup>+</sup> T cells, 421 terms in DCs, and 62  
259 terms in NK. To better understand the context of gene dysregulation observed within cell types, and  
260 uncover which cellular processes may be affected, functional enrichment analysis of gene ontology  
261 terms and pathways was performed. Informative enriched terms for each set of DEGs among GI  
262 disorders (CD, UC, EoD, and EoE) within each cell type is shown in **Figure 4**. A full list of  
263 significantly enriched GO terms and pathways can be found in **Supplementary File 1 Tables G-K**.

264 While there were few enriched GO terms and pathways detected in common among genes  
265 dysregulated in CD, UC, EoD, and EoE, there was evidence of altered expression of  
266 immunoglobulins in B cells among all GI disorders compared to controls, including antigen binding  
267 (GO:0003823) and IgG immunoglobulin complex (GO:0071735) (**Figure 4; Supplementary File 1**  
268 **Table G**). Furthermore, calcium homeostasis-associated terms were enriched among DEGs for each  
269 GI disorder, terms included regulation of calcium ion transport (GO:0051924) for DEGs found in CD  
270 and UC in CD8<sup>+</sup> T cells and among DEGs in both EoE and EoD in DCs and regulation of calcium-  
271 mediated signaling (GO:0050848) for DEGs detected in CD and UC in CD8<sup>+</sup> T cells and among  
272 DEGs found in EoE within B cells and DCs (**Figure 3; Supplementary File 1 Tables G, I, and J**)

273 Similarities within eosinophilic disorders (EoD and EoE) were also present. GO terms and pathways  
274 associated with cell cycle activity in CD4<sup>+</sup> T cells were enriched among genes differentially  
275 expressed in EoD and EoE compared to controls, including Reactome cell cycle mitotic (M5336),  
276 Reactome cell cycle (M543) and mitotic cell cycle process (GO:1903047). Other commonly enriched  
277 terms among DEGs found in EoD and EoE included transition metal ion binding (GO:0046914)  
278 within NK cells and PID AP1 pathway (M167) within CD4<sup>+</sup> T cells (**Figure 3; Supplementary File**  
279 **1 Tables H and K**)


280 Specifically, among DEGs in CD, there was an enrichment of GO terms and pathways associated  
281 with endoplasmic reticulum function and protein folding in B cells, such as endoplasmic reticulum  
282 protein-containing complex (GO:0140534), endoplasmic reticulum chaperone complex  
283 (GO:0034663), and Reactome pathways ATF6 alpha activates chaperone genes (M801). Notably,  
284 among DEGs in EoD, there was enrichment of terms associated with the p38 MAPK pathway in  
285 CD4<sup>+</sup> T cells, including p38MAPK cascade (GO:0038066) and regulation of p38 MAPK cascade  
286 (GO:1900744). Analysis of DEGs within EoE yielded enrichment of zinc ion binding (GO:0008270)  
287 within B cells (**Figure 3; Supplementary File 1 Tables G and H**).

### 288 **Protein-Protein Interaction Networks of DEGs**

289 We generated networks for protein interaction among significant DEGs to identify relationships from  
290 curated databases and mined from high-throughput studies and primary literature. A selection of the

291 major components of PPI networks generated in STRING and enhanced with Cytoscape illustrating  
 292 the relationships of DEGs detected within cell types are shown in **Figure 4**. Additionally, genes  
 293 associated with enriched gene ontology terms and pathways of interest have been highlighted.

294 **Figure 4.** Major component of protein-protein interaction (PPI) network generated with **A)**  
 295 differentially expressed genes (DEGs) detected in B cells of individuals with CD, **B)** DEGs detected  
 296 in CD8<sup>+</sup> T cells from individuals with UC, **C)** DEGs detected in CD4<sup>+</sup> T cells from individuals with  
 297 EoD, and **D)** DEGs detected in CD4<sup>+</sup> T cells from individuals with EoE. Node color indicates the  
 298 direction of fold change of expression of each gene, with red indicating upregulation of gene  
 299 gene expression in patients with GI disorders compared to control and blue indicating downregulation of  
 300 gene expression in patients with GI disorders compared to control. Node outline color indicates  
 301 enriched functional annotations detected in STRING.



302

303 In B cells of individuals with CD, most of the genes associated with endoplasmic reticulum terms are  
 304 downregulated. Additionally, many of those genes are associated with chaperone functions of the  
 305 endoplasmic reticulum (**Figure 4A**). We also observed widespread downregulation of DEGs within  
 306 CD8<sup>+</sup> T cells among individuals with UC, including markers of cytotoxicity (*CCL5*, *FGFBP2*,

307 *GZMA*, *GZMB*, *GZMH*, *IFNG*, *NKG7*, and *PRF1*) along with the upregulation *NOG*, *REG4*, and  
308 *AIF1* (**Figure 4B**). We further illustrate through PPIs, the similarity of gene dysregulation and  
309 dominance of DEGs associated with the cell cycle for both EoE and EoD within CD4<sup>+</sup> T cells  
310 (**Figure 4C and D**), highlighting the similarity of these disorders. However, within these networks  
311 we can also see distinct profiles of genes dysregulated between EoE and EoD, including the  
312 downregulation of genes associated with p38 MAPK (*GADD45B*, *GADD45G*, and *DUSP1*) in EoD  
313 (**Figure 4C**).

## 314 Discussion

315 Aberrant immune signaling due to genetic and environmental factors contributes to the development  
316 of GI disorders (31). In this study we focused on the characterization of transcriptomic patterns in  
317 PBMCs of pediatric patients with active CD, UC, EoE, and EoD to identify genes and pathways  
318 associated with active inflammation and the pathogenesis of each disease. Insights into these  
319 transcriptomic phenotypes provide potential indicators of active inflammation and identify genetic  
320 markers for improved diagnosis, as well as possible therapeutic targets for treatment.

321 Genes showing similar patterns of differential expression among all GI disorders (CD, UC, EoE, and  
322 EoD) include the upregulation of *MTRNR2L8* within six level one cell types (B, CD4<sup>+</sup> T, CD8<sup>+</sup> T,  
323 DC, NK, and other T), may be helpful in identifying active inflammation in GI disorders.  
324 *MTRNR2L8* is believed to be a marker of cellular stress (32), and upregulation of *MTRNR2L8* has  
325 been observed among PBMCs of patients with primary mitochondrial disease (33) and among  
326 immune cell types in individuals with aspirin-exacerbated respiratory disease (34).

327 The common upregulation of *MTRNR2L1* for EoD and EoE was identified in four level one cell types  
328 (B, CD4<sup>+</sup> T, CD8<sup>+</sup> T, and DC). Similar to *MTRNR2L8*, *MTRNR2L1* also appears to be upregulated in  
329 response to cellular stress (32) and has been found to be upregulated in myeloid cells of patients with  
330 autoimmune disorders (35). There was also enrichment of functional terms associated with cell cycle  
331 activity in CD4<sup>+</sup> T cells among DEGs in EoE and EoD compared to controls, prominent among  
332 which were Reactome cell cycle mitotic (M5336), Reactome cell cycle (M543) and mitotic cell cycle  
333 process (GO:1903047), which may be indicative of dysregulation associated with Th2-mediated  
334 inflammation; genes associated with cell cycle progression and proliferation, specifically *MKI76*,  
335 *RRM2*, and *TOP2A*, which were found among upregulated cell cycle genes in EoD and EoE, have  
336 also been observed to be upregulated in the epithelium of asthmatics with high levels of Th2 (36).

337 Functional analysis of DEGs in CD detected in B cells yielded enrichment of terms associated with  
338 endoplasmic reticulum function and protein folding. Endoplasmic reticulum stress and the  
339 dysregulation of the unfolded protein response have been implicated in the development of IBD,  
340 which are essential for the maintenance of homeostasis in both the intestine and immune cells (37,  
341 38). Furthermore, the specific enrichment of Reactome pathway ATF6 alpha activates chaperone  
342 genes in CD is supported by evidence of that diminished *ATF6* activity can contribute to intestinal  
343 barrier dysfunction in mouse models of IBD (39).

344 In individual with EoD, upregulation of *CCR9* and downregulation of *GADD45B* and *GADD45G*  
345 was found in CD4<sup>+</sup> T cells of patients compared to controls. *CCR9* has demonstrated to play a key  
346 role in Th2-mediated inflammation, with *Ccr9*<sup>-/-</sup> mice treated with ovalbumin to induce allergic  
347 inflammation exhibiting an impaired immune response and diminished recruitment of eosinophils to  
348 inflamed tissue (40). Deficiency in *GADD45* expression has been associated with autoimmune  
349 disease (41), and the increased expression of *GADD45G* through administration of IL-27, has been

350 shown to attenuate Th2-mediated allergic possibly through the activation of the p38 MAPK pathway  
351 (42), a pathway that was found to be enriched among DEGs in CD4<sup>+</sup> T cells in EoD.

352 Among identified DEGs in EoE relative to controls was *EGR1* in three level one cell types (B, CD4<sup>+</sup>  
353 T, and CD8<sup>+</sup> T cells) and several level two cell types, including naïve CD8<sup>+</sup> T cells and CD4<sup>+</sup> TCM  
354 cells. Among CD4<sup>+</sup> T cells, *EGR1* is preferentially expressed by Th2 and plays a role in the  
355 production of IL-4 cytokines (43), which mediate the allergic inflammatory response (44).  
356 Additionally, increased intracellular zinc levels have been shown to upregulate *EGR1* (45).  
357 Relevantly, the term zinc ion binding was enriched among DEGs in B cells in EoE. Zinc exposure  
358 has been demonstrated to elicit cellular damage (46), induce eosinophilia in mice, and evoke Th2  
359 cytokine production (47). Furthermore, dysregulation of zinc signaling resulting from depletion of  
360 zinc within mucosal tissues and the release of zinc from airway discharge has been associated with  
361 eosinophilia (48). Together, these data support evidence that zinc homeostasis is critical in regulating  
362 inflammatory responses (49) and suggests that zinc homeostasis may be involved the development of  
363 eosinophilic disorders.

364 Several DEGs were found to be dysregulated between UC and controls within CD8<sup>+</sup> T cells, such as  
365 the downregulation of several genes involved in T cell cytotoxicity (*CCL5*, *FGFBP2*, *GZMA*, *GZMB*,  
366 *GZMH*, *IFNG*, *NKG7*, and *PRF1*). Previously, it has been shown that while elevated levels of *GZMB*  
367 were present in mucosal biopsies of treatment-naïve individuals with CD, there was not upregulation  
368 of *GZMB* in treatment-naïve individuals with UC compared to controls, suggesting enhanced CD8<sup>+</sup> T  
369 cytotoxicity in CD but not UC (50). Reduced T-cell cytotoxicity has also been detected in sub-  
370 populations of individuals with UC, including those who develop persistent low-grade dysplasia (51).  
371 Additionally, widespread upregulation of *XIST* was detected within five level one cell types (B, CD4<sup>+</sup>  
372 T, DC, monocytes, and NK) in UC compared to controls. In mouse models of IBD, *Xist* expression  
373 has been demonstrated to be upregulated after inducing colitis, and silencing of *Xist* in these models  
374 has shown to reduce colitis-associated symptoms (52). Moreover, previous transcriptome analysis of  
375 intestinal mucosa biopsies from individuals with UC have identified *XIST* as a key mediator of  
376 inflammation within this disease, as well as a possible therapeutic target (53).

377 The results of this study hold future implications for clinicians. DEGs that identify active  
378 inflammation may be of utility in differentiating patients with active disease and disease in remission  
379 without the need for more invasive endoscopy. Additionally, these DEGs show promise of indicating  
380 degree of inflammation allowing clinicians to stratify severity of active disease and adjust treatment  
381 plans accordingly. Zinc homeostasis dysregulation in eosinophilic disorders provides a potential  
382 treatment target in a condition where presently there are few pharmacologic treatment options (54).  
383 Patients with EoE are known to have zinc deficiencies associated with elimination diets (55), but  
384 further investigation as to how these diets affect overall zinc regulation is needed.

385 This study demonstrates preliminary evidence for the utility of single-cell RNA-sequencing of patient  
386 blood cells to characterize the genomic landscape of pediatric IBD subtypes and eosinophilic  
387 disorders. These data indicate both overlapping and distinct DEGs, enriched Gene Ontology terms,  
388 and enriched pathways associated the pathogenesis of inflammation among individuals with CD, UC,  
389 EoD, and EoE, offering further insight into which genes and pathways may serve as useful markers  
390 of disease in the peripheral blood mononuclear cells of patients.

391

393 **References**

- 394 1. Abraham C, Cho JH. MECHANISMS OF DISEASE Inflammatory Bowel Disease. New Engl  
395 J Med. 2009;361(21):2066-78.
- 396 2. Silva FAR, Rodrigues BL, Ayrizono MDS, Leal RF. The Immunological Basis of  
397 Inflammatory Bowel Disease. Gastroent Res Pract. 2016;2016.
- 398 3. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing  
399 incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review.  
400 Gastroenterology. 2012;142(1):46-54.
- 401 4. Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol.  
402 2015;12(12):720-7.
- 403 5. Furuta GT, Katzka DA. Eosinophilic Esophagitis. New Engl J Med. 2015;373(17):1640-8.
- 404 6. Bass JA, Friesen CA, Deacy AD, Neilan NA, Bracken JM, Shakhnovich V, et al.  
405 Investigation of potential early histologic markers of pediatric inflammatory bowel disease. BMC  
406 Gastroenterol. 2015;15:1-7.
- 407 7. Jacobs I, Ceulemans M, Wauters L, Breynaert C, Vermeire S, Verstockt B, et al. Role of  
408 Eosinophils in Intestinal Inflammation and Fibrosis in Inflammatory Bowel Disease: An Overlooked  
409 Villain? Front Immunol. 2021;12:754413.
- 410 8. Berg DR, Colombel JF, Ungaro R. The Role of Early Biologic Therapy in Inflammatory  
411 Bowel Disease. Inflamm Bowel Dis. 2019;25(12):1896-905.
- 412 9. Kelay A, Tullie L, Stanton M. Surgery and paediatric inflammatory bowel disease. Transl  
413 Pediatr. 2019;8(5):436-48.
- 414 10. Urquhart SA, Quinn KP, Ravi K, Loftus EV, Jr. The Clinical Characteristics and Treatment  
415 Outcomes of Concomitant Eosinophilic Esophagitis and Inflammatory Bowel Disease. Crohns  
416 Colitis 360. 2021;3(2):otab018.
- 417 11. Sawczenko A, Ballinger AB, Savage MO, Sanderson IR. Clinical features affecting final  
418 adult height in patients with pediatric-onset Crohn's disease. Pediatrics. 2006;118(1):124-9.
- 419 12. Heuschkel R, Salvestrini C, Beattie RM, Hildebrand H, Walters T, Griffiths A. Guidelines for  
420 the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis.  
421 2008;14(6):839-49.
- 422 13. Greenley RN, Hommel KA, Nebel J, Raboin T, Li SH, Simpson P, et al. A meta-analytic  
423 review of the psychosocial adjustment of youth with inflammatory bowel disease. J Pediatr Psychol.  
424 2010;35(8):857-69.
- 425 14. Cohen NA, Rubin DT. New targets in inflammatory bowel disease therapy: 2021. Curr Opin  
426 Gastroenterol. 2021;37(4):357-63.
- 427 15. Hart AL, Al-Hassi HO, Rigby RJ, Bell SJ, Emmanuel AV, Knight SC, et al. Characteristics of  
428 intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology. 2005;129(1):50-65.
- 429 16. Coombes JL, Powrie F. Dendritic cells in intestinal immune regulation. Nat Rev Immunol.  
430 2008;8(6):435-46.

- 431 17. Chaudhry A, Rudensky AY. Control of inflammation by integration of environmental cues by  
432 regulatory T cells. *J Clin Invest.* 2013;123(3):939-44.
- 433 18. Weaver CT, Elson CO, Fouser LA, Kolls JK. The Th17 pathway and inflammatory diseases  
434 of the intestines, lungs, and skin. *Annu Rev Pathol.* 2013;8:477-512.
- 435 19. Ohnmacht C, Marquee R, Presley L, Sawa S, Lochner M, Eberl G. Intestinal microbiota,  
436 evolution of the immune system and the bad reputation of pro-inflammatory immunity. *Cellular*  
437 *Microbiology.* 2011;13(5):653-9.
- 438 20. Mishra A, Hogan SP, Lee JJ, Foster PS, Rothenberg ME. Fundamental signals that regulate  
439 eosinophil homing to the gastrointestinal tract. *Journal of Clinical Investigation.* 1999;103(12):1719-  
440 27.
- 441 21. Burczynski ME, Peterson RL, Twine NC, Zuberek KA, Brodeur BJ, Casciotti L, et al.  
442 Molecular classification of Crohn's disease and ulcerative colitis patients using transcriptional  
443 profiles in peripheral blood mononuclear cells. *J Mol Diagn.* 2006;8(1):51-61.
- 444 22. Martin JC, Chang C, Boschetti G, Ungaro R, Giri M, Grout JA, et al. Single-Cell Analysis of  
445 Crohn's Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-  
446 TNF Therapy. *Cell.* 2019;178(6):1493-508.
- 447 23. Chen P, Zhou GS, Lin JX, Li L, Zeng ZR, Chen MH, et al. Serum Biomarkers for  
448 Inflammatory Bowel Disease. *Front Med-Lausanne.* 2020;7.
- 449 24. Kang HM, Subramaniam M, Targ S, Nguyen M, Maliskova L, McCarthy E, et al.  
450 Multiplexed droplet single-cell RNA-sequencing using natural genetic variation. *Nat Biotechnol.*  
451 2018;36(1):89-94.
- 452 25. Hao Y, Stuart T, Kowalski MH, Choudhary S, Hoffman P, Hartman A, et al. Dictionary  
453 learning for integrative, multimodal and scalable single-cell analysis. *Nat Biotechnol.*  
454 2024;42(2):293-304.
- 455 26. Hao YH, Hao S, Andersen-Nissen E, Mauck WM, Zheng SW, Butler A, et al. Integrated  
456 analysis of multimodal single-cell data. *Cell.* 2021;184(13):3573-87.
- 457 27. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential  
458 expression analysis of digital gene expression data. *Bioinformatics.* 2010;26(1):139-40.
- 459 28. Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene Suite for gene list enrichment analysis  
460 and candidate gene prioritization. *Nucleic Acids Res.* 2009;37:W305-W11.
- 461 29. Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING  
462 database in 2023: protein-protein association networks and functional enrichment analyses for any  
463 sequenced genome of interest. *Nucleic Acids Res.* 2023;51(D1):D638-D46.
- 464 30. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: A  
465 software environment for integrated models of biomolecular interaction networks. *Genome Res.*  
466 2003;13(11):2498-504.
- 467 31. Turpin W, Goethel A, Bedrani L, Croitoru K. Determinants of IBD Heritability: Genes, Bugs,  
468 and More. *Inflamm Bowel Dis.* 2018;24(6):1133-48.
- 469 32. Yen K, Lee C, Mehta H, Cohen P. The emerging role of the mitochondrial-derived peptide  
470 humanin in stress resistance. *J Mol Endocrinol.* 2013;50(1):R11-R9.

- 471 33. Gordon-Lipkin EM, Banerjee P, Franco JLM, Tarasenko T, Kruk S, Thompson E, et al.  
472 Primary oxidative phosphorylation defects lead to perturbations in the human B cell repertoire. *Front*  
473 *Immunol.* 2023;14:1142634.
- 474 34. Bangert C, Villazala-Merino S, Fahrenberger M, Krausgruber T, Bauer WM, Stanek V, et al.  
475 Comprehensive Analysis of Nasal Polyps Reveals a More Pronounced Type 2 Transcriptomic Profile  
476 of Epithelial Cells and Mast Cells in Aspirin-Exacerbated Respiratory Disease. *Frontiers in*  
477 *Immunology.* 2022;13.
- 478 35. Taft J, Markson M, Legarda D, Patel R, Chan M, Malle L, et al. Human TBK1 deficiency  
479 leads to autoinflammation driven by TNF-induced cell death. *Cell.* 2021;184(17):4447-63.
- 480 36. Hachim MY, Elemam NM, Ramakrishnan RK, Salameh L, Olivenstein R, Hachim IY, et al.  
481 Derangement of cell cycle markers in peripheral blood mononuclear cells of asthmatic patients as a  
482 reliable biomarker for asthma control (vol 11, 11873, 2021). *Sci Rep-Uk.* 2021;11(1).
- 483 37. Cao SS. Endoplasmic Reticulum Stress and Unfolded Protein Response in Inflammatory  
484 Bowel Disease. *Inflamm Bowel Dis.* 2015;21(3):636-44.
- 485 38. Li C, Grider JR, Murthy KS, Bohl J, Rivet E, Wieghard N, et al. Endoplasmic Reticulum  
486 Stress in Subepithelial Myofibroblasts Increases the TGF- $\beta$ 1 Activity That Regulates Fibrosis in  
487 Crohn's Disease. *Inflamm Bowel Dis.* 2020;26(6):809-19.
- 488 39. Huang SS, Xie Z, Han J, Wang HL, Yang G, Li MY, et al. Protocadherin 20 maintains  
489 intestinal barrier function to protect against Crohn's disease by targeting ATF6. *Genome Biol.*  
490 2023;24(1).
- 491 40. López-Pacheco C, Soldevila G, Du Pont G, Hernández-Pando R, García-Zepeda EA. CCR9 Is  
492 a Key Regulator of Early Phases of Allergic Airway Inflammation. *Mediat Inflamm.* 2016;2016.
- 493 41. Schmitz I. Gadd45 Proteins in Immunity. *Gadd45 Stress Sensor Genes.* 2013;793:51-68.
- 494 42. Su XQ, Pan J, Bai FX, Yuan HL, Dong N, Li DD, et al. IL-27 attenuates airway inflammation  
495 in a mouse asthma model via the STAT1 and GADD45 $\gamma$ /p38 MAPK pathways. *J Transl Med.*  
496 2016;14.
- 497 43. Lohoff M, Giaisi M, Köhler R, Casper B, Krammer PH, Li-Weber M. Early Growth  
498 Response Protein-1 (Egr-1) Is Preferentially Expressed in T Helper Type 2 (Th2) Cells and Is  
499 Involved in Acute Transcription of the Th2 Cytokine Interleukin-4. *J Biol Chem.* 2010;285(3):1643-  
500 52.
- 501 44. Ricci M, Matucci A, Rossi O. IL-4 as a key factor influencing the development of allergen-  
502 specific Th2-like cells in atopic individuals. *J Invest Allerg Clin.* 1997;7(3):144-50.
- 503 45. Barbato JC, Catanescu O, Murray K, DiBello PM, Jacobsen DW. Targeting of  
504 metallothionein by L-homocysteine - A novel mechanism for disruption of zinc and redox  
505 homeostasis. *Arterioscl Throm Vas.* 2007;27(1):49-54.
- 506 46. Fukui H, Horie M, Endoh S, Kato H, Fujita K, Nishio K, et al. Association of zinc ion release  
507 and oxidative stress induced by intratracheal instillation of ZnO nanoparticles to rat lung. *Chem Biol*  
508 *Interact.* 2012;198(1-3):29-37.
- 509 47. Huang KL, Lee YH, Chen HI, Liao HS, Chiang BL, Cheng TJ. Zinc oxide nanoparticles  
510 induce eosinophilic airway inflammation in mice. *J Hazard Mater.* 2015;297:304-12.



511 48. Suzuki M, Ramezanzpour M, Cooksley C, Lee TJ, Jeong B, Kao S, et al. Zinc-depletion  
512 associates with tissue eosinophilia and collagen depletion in chronic rhinosinusitis. *Rhinology*.  
513 2020;58(5):451-9.

514 49. Devirgiliis C, Zalewski PD, Perozzi G, Murgia C. Zinc fluxes and zinc transporter genes in  
515 chronic diseases. *Mutat Res-Fund Mol M*. 2007;622(1-2):84-93.

516 50. Jenkins D, Seth R, Kummer JA, Scott BB, Hawkey CJ, Robins RA. Differential levels of  
517 granzyme B, regulatory cytokines, and apoptosis in Crohn's disease and ulcerative colitis at first  
518 presentation. *J Pathol*. 2000;190(2):184-9.

519 51. Kotsafti A, D'Incà R, Scarpa M, Fassan M, Angriman I, Mescoli C, et al. Weak Cytotoxic T  
520 Cells Activation Predicts Low-Grade Dysplasia Persistence in Ulcerative Colitis. *Clin Transl*  
521 *Gastroen*. 2019;10.

522 52. Gu D, Cao T, Yi S, Li X, Liu Y. Transcription suppression of GABARAP mediated by  
523 lncRNA XIST-EZH2 interaction triggers caspase-11-dependent inflammatory injury in ulcerative  
524 colitis. *Immunobiology*. 2024;229(3):152796.

525 53. Xu M, Kong Y, Chen N, Peng W, Zi R, Jiang M, et al. Identification of Immune-Related  
526 Gene Signature and Prediction of CeRNA Network in Active Ulcerative Colitis. *Front Immunol*.  
527 2022;13:855645.

528 54. Tamarit-Sebastian S, Ferrer-Soler FM, Lucendo AJ. Current options and investigational drugs  
529 for the treatment of eosinophilic esophagitis. *Expert Opin Investig Drugs*. 2022;31(2):193-210.

530 55. Votto M, De Filippo M, Lenti MV, Rossi CM, Di Sabatino A, Marseglia GL, et al. Diet  
531 Therapy in Eosinophilic Esophagitis. Focus on a Personalized Approach. *Front Pediatr*.  
532 2021;9:820192.

533